Maxim

"SAN DIEGO, Sep 20, 2004 (BUSINESS WIRE) -- Maxim Pharmaceuticals (Nasdaq:MAXM) (SSE:MAXM) today announced that its confirmatory Phase 3 trial (M104) of the investigational drug Ceplene(TM) (histamine dihydrochloride) in combination with Interleukin-2 (IL-2) for the treatment of advanced malignant melanoma patients with liver metastases failed to demonstrate an improvement in overall patient survival, the primary endpoint."

Kursras!